Federal HB9547 directs the Department of Defense to report on emerging treatments for treatment-resistant PTSD in veterans and servicemembers.
Federal HB9547, the Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026, mandates the Assistant Secretary of Defense for Health Affairs to submit a report to Congress within 180 days of enactment. The report examines the operational relevance, safety, dosing, and feasibility of data from a specific clinical trial on PTSD treatments, particularly focusing on members of the Armed Forces and those transitioning to civilian life.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.